Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth

The osteosarcoma treatment pipeline is gradually expanding, with emerging therapies such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk; SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug rezetecan (GSK), Olaparib with Ceralaserti (AstraZeneca), OMO-103 (Peptomyc), Eflornithine (DFMO) and AMXT 1501 (Aminex Therapeutics), PEEL-224 (Peel Therapeutics), ADCE-D01 (ADCendo), Dendritic cell-based vaccine (CellxLife), LNTH-2403 (Lantheus), and other investigational agents representing promising assets that could reshape the future treatment landscape, particularly in relapsed and metastatic settings.

LAS VEGAS, Sept. 3, 2026 /PRNewswire/ -- Osteosarcoma treatment typically involves a multimodal approach combining surgical tumor removal with systemic chemotherapy and, in selected patients, radiotherapy. Current treatment recommendations include established chemotherapy agents such as methotrexate, doxorubicin, cisplatin, and ifosfamide. For individuals experiencing relapsed, refractory, or metastatic disease, available second-line approaches include high-dose ifosfamide, etoposide, regorafenib, sorafenib, radium-223 dichloride, and everolimus.

Despite these options, the treatment landscape continues to face substantial unmet needs because only a limited number of therapies are specifically approved for osteosarcoma. In the United States, levoleucovorin (KHAPZORY) has received FDA approval, while mifamurtide (MEPACT) is approved by the European Commission for use across the European Union.

Find out the major differences between osteosarcoma vs Ewing sarcoma @ https://www.delveinsight.com/report-store/osteosarcoma-market

Emerging Osteosarcoma Therapies and Changing Treatment Landscape

The osteosarcoma pipeline is increasingly shifting toward precision medicine, immunotherapy, targeted approaches, and antibody-drug conjugates. Prominent candidates include OST-HER2, a HER2-directed cellular immunotherapy designed to activate tumor-specific immune responses; naxitamab-gqgk (DANYELZA), which recognizes GD2-expressing cancer cells; Vactosertib, which inhibits TGF-β signaling involved in tumor progression and metastasis; and Risvutatug Rezetecan, an ADC developed to deliver cytotoxic activity directly to cancer cells.

However, much of the pipeline remains concentrated in early clinical development, particularly Phase II trials. The limited number of late-stage studies means that substantial randomized evidence demonstrating improvements in overall survival, event-free survival, and durable responses remains unavailable. This evidence gap can delay regulatory progress and contribute to differences in treatment access across major markets.

According to oncology experts at DelveInsight, continued investment in targeted therapies, immunotherapies, tyrosine kinase inhibitors, and cell-based treatment strategies could broaden therapeutic options for patients with difficult-to-treat osteosarcoma.

Osteosarcoma Market Outlook Through 2036

DelveInsight estimates that the osteosarcoma market across the seven major markets—the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was worth approximately USD 60 million in 2025. The market is forecast to grow at a CAGR of 9% through 2036.

Growth is expected to be supported by increasing research and development investment, the introduction of novel targeted therapies, improvements in multimodal treatment strategies, and greater focus on relapsed, metastatic, and treatment-resistant disease.

OS Therapies' OST-HER2

HER2-targeted cancer vaccine

OST-HER2 is an investigational HER2-targeted immunotherapy being developed for HER2-expressing cancers, including osteosarcoma. The therapy is designed to activate HER2-specific T cells and encourage the immune system to identify and destroy malignant cells. Following administration, the vector is taken up by antigen-presenting cells, which subsequently stimulate a targeted immune response.

Research, including studies involving canine osteosarcoma, has indicated potential benefits in reducing recurrence and metastatic progression. OST-HER2 is currently being studied as a second-line treatment in a Phase IIb trial, with OS Therapies planning to pursue a BLA through the FDA Accelerated Approval pathway.

In August 2026, OS Therapies announced that the FDA had accepted its request for a Type C Statistical Methods meeting to discuss 2.5-year overall survival data from the Phase IIb study. The company also anticipated reporting interim three-year overall survival data in September 2026. Earlier in March 2026, the EMA's Committee for Advanced Therapies granted OST-HER2 ATMP designation for pulmonary recurrence in resected osteosarcoma. The therapy has also received Fast Track and Orphan Drug designations in the United States.

The osteosarcoma market is expected to evolve gradually, with OST-HER2 projected to emerge as a potential key asset, generating approximately USD 37 million across the 7MM by 2036, as per Thakur.

Iterion Therapeutics' Tegavivint

TBL1X protein inhibitors

Tegavivint is designed to inhibit TBL1, an important co-activator involved in Wnt-mediated gene transcription. By targeting this mechanism, the therapy aims to suppress β-catenin-driven oncogenic activity while potentially avoiding some toxicities associated with upstream Wnt inhibition.

The candidate is being evaluated in combination with gemcitabine in pediatric patients with relapsed or refractory osteosarcoma. It has received Orphan Drug Designation and Rare Pediatric Disease Designation, with topline results expected in the second half of 2027. In February 2026, Iterion announced that the first patient had been dosed in the clinical study sponsored by Emory University and conducted at Children's Healthcare of Atlanta.

Discover more about the new treatment options for osteosarcoma @ Osteosarcoma Bone Cancer - https://www.delveinsight.com/sample-request/osteosarcoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

SERB Pharmaceutical's DANYELZA

Antibody-dependent cell cytotoxicity (ADCC)

DANYELZA (naxitamab-gqgk) is a humanized anti-GD2 monoclonal antibody designed to recognize GD2-expressing tumor cells and promote antibody-dependent cellular cytotoxicity. Early investigations have reported manageable safety and encouraging activity, although additional evidence is required to establish its safety and effectiveness in older osteosarcoma populations.

SERB Pharmaceuticals acquired Y-mAbs Therapeutics in September 2025, adding DANYELZA to its rare oncology portfolio and strengthening its capabilities in targeted cancer therapeutics.

Sadaf Javed, Functional Head of Forecasting and Analytics at DelveInsight, stated that the asset carries a "selective responder" profile rather than broad efficacy, with commercial potential constrained by small eligible populations and uncertain tolerability in older osteosarcoma patients. Overall, it is viewed as a niche orphan oncology product with modest expansion upside rather than a high-growth oncology franchise.

Aminex Therapeutics' AMXT 1501 + DFMO

Polyamine uptake inhibitors

Aminex Therapeutics is developing AMXT 1501, an oral proprietary polyamine uptake inhibitor, in combination with DiFluoroMethylOrnithine (DFMO or eflornithine). The combination targets complementary components of polyamine metabolism and is intended to enhance immune-mediated antitumor activity.

The approach is being investigated as an immuno-oncology strategy across solid tumors, including osteosarcoma, and represents an alternative mechanism that could complement conventional anticancer treatments.

To know more about osteosarcoma drug development, visit @ Osteosarcoma Treatment Pipeline - https://www.delveinsight.com/sample-request/osteosarcoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

MedPacto's Vactosertib

TGF-β1 kinase inhibitor

Vactosertib (TEW-7197) is a TGF-β1 signaling inhibitor designed to modify the tumor microenvironment. Abnormal TGF-β activity can suppress immune responses, support metastatic processes, promote tumor-associated fibrosis, and contribute to resistance against anticancer therapies.

By interfering with these pathways, vactosertib could potentially improve immune-cell penetration and enhance the effectiveness of other treatments. The FDA granted Fast Track Designation to vactosertib in January 2023 for relapsed/refractory metastatic osteosarcoma. It previously received Rare Pediatric Disease Designation, while the European Commission granted Orphan Drug Designation in July 2023.

According to Javed, vactosertib is a high-upside but still unproven platform asset, with valuation and outlook hinging on whether later-stage studies can confirm consistent response rates and clinically meaningful durability in a broader population.

GSK's Risvutatug Rezetecan

ADC targeting B7-H3

Risvutatug rezetecan (Ris-Rez; GSK5764227; HS-20093) is an investigational ADC targeting B7-H3, a protein expressed across multiple solid tumors. The therapy is designed to bind B7-H3-positive cancer cells and deliver a cytotoxic payload directly to them, potentially improving tumor selectivity.

The candidate is being evaluated in GSK's global EMBOLD development program across several tumor types. In 2025, the FDA granted Breakthrough Therapy Designation to risvutatug rezetecan for patients with late-line relapsed or refractory osteosarcoma, highlighting its potential in a population with significant unmet medical needs.

Explore more about recent advancements in osteosarcoma treatments @ Osteosarcoma Treatment Market- https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Peel Therapeutics' PEEL-224

DNA topoisomerase I inhibitors

PEEL-224 is a polymer-based nanocarrier containing multiple small molecules and is being investigated as a potential treatment for aggressive cancers. Its active component is derived from camptothecin, a naturally occurring compound that targets topoisomerase I and disrupts DNA replication.

The polymer-based design aims to improve drug delivery while reducing toxicity and limiting drug efflux through the ABCG2 multidrug transporter. Preclinical research has reported sustained complete responses in certain aggressive solid-tumor models, suggesting potential activity against treatment-resistant disease.

ADCendo's ADCE-D01

DNA topoisomerase I inhibitors

ADCE-D01 is a first-in-class ADC targeting uPARAP, a receptor highly expressed in several mesenchymal malignancies, including osteosarcoma, soft tissue sarcoma, GIST, mesothelioma, and glioblastoma. Its design combines a uPARAP-binding antibody with a protease-cleavable linker and deruxtecan payload.

Preclinical studies have shown significant antitumor activity across multiple models and supported its further clinical development. ADCE-D01 is currently being studied in a multicenter Phase I/II trial evaluating safety, tolerability, and dosing in patients with soft tissue sarcoma across the United States and Europe. The FDA has granted Fast Track and Orphan Drug designations for soft tissue sarcoma.

Conclusion

Osteosarcoma remains an area of significant unmet medical need, particularly for patients with relapsed, metastatic, or refractory disease. Although current management relies heavily on surgery and chemotherapy, the emerging pipeline is introducing innovative approaches, including immunotherapies, ADCs, targeted inhibitors, and metabolic strategies. Candidates such as OST-HER2, tegavivint, DANYELZA, vactosertib, risvutatug rezetecan, PEEL-224, and ADCE-D01 could broaden future treatment choices if clinical studies confirm meaningful efficacy and safety. With the market projected to grow through 2036, continued investment, stronger clinical evidence, and successful regulatory outcomes will be critical to transforming osteosarcoma care and addressing persistent therapeutic gaps worldwide.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com